Minimum Acceptance Threshold Met in Exchange Proposal Between Two Biotech Firms

(MAINZ, Germany, December 3, 2025) – The biotech firm BioNTech (Nasdaq: BNTX) recently announced that the minimum condition for its exchange offer involving fellow biotech firm CureVac N.V. (Nasdaq: CVAC) has been satisfied.

As of 9:00 a.m. Eastern Time on December 3, 2025, a total of 184,071,410 ordinary shares of CureVac were validly tendered and not properly withdrawn. This figure represents approximately 81.74% of CureVac’s issued and outstanding shares.

With the minimum acceptance threshold met, all validly tendered shares will be accepted. BioNTech will now proceed to deliver BioNTech American Depositary Shares (ADSs) (and/or cash in lieu of fractional shares) to the tendering shareholders, thereby closing the transaction. All closing conditions related to the post-offer reorganization have also been satisfied.

BioNTech further announced the commencement of the subsequent offering period. CureVac shareholders who have not yet tendered their shares may still do so during this period, which will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025.

Following the expiration of the subsequent offering period, the parties will promptly initiate the post-offer reorganization. This process will result in non-tendering CureVac shareholders also receiving BioNTech ADSs (and/or cash in lieu of fractional shares). It is important to note that these shareholders will generally be subject to a 15% Dutch dividend withholding tax.

Soon after the post-offer reorganization is complete, shares held by non-tendering CureVac shareholders will cease to be tradable on any national stock exchange and may be subject to additional transfer restrictions.

Source: https://finance.yahoo.com/news/biontech-achieves-minimum-condition-curevac-140100380.html